The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
about
Methylhonokiol attenuates neuroinflammation: a role for cannabinoid receptors?Pathological and protective roles of glia in chronic painProgress toward pharmacotherapies for cannabis-use disorder: an evidence-based reviewModulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addictionPharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategiesInhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addictionA cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitisEndocannabinoid-mediated synaptic plasticity and addiction-related behaviorA Novel Closed-Head Model of Mild Traumatic Brain Injury Using Focal Primary Overpressure Blast to the Cranium in Mice.Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats.Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation.Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.Amelioration of Cognitive Dysfunction in APP/PS1 Double Transgenic Mice by Long-Term Treatment of 4-O-Methylhonokiol.Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown.Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivativesCB2: a cannabinoid receptor with an identity crisisChemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoidsChronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawalThe Pharmacological Basis of Cannabis Therapy for Epilepsy.Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury.Protective Effects of Quercetin on Mitochondrial Biogenesis in Experimental Traumatic Brain Injury via the Nrf2 Signaling Pathway.Motor, visual and emotional deficits in mice after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse agonist SMM-189Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDSThe spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain?Cannabinoid receptor expression in HIV encephalitis and HIV-associated neuropathologic comorbidities.Antagonism of cannabinoid receptor 2 pathway suppresses IL-6-induced immunoglobulin IgM secretion.Endocannabinoids and traumatic brain injuryEndocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.Differential immune mechanism to HIV-1 Tat variants and its regulation by AEA [corrected].4'-O-methylhonokiol increases levels of 2-arachidonoyl glycerol in mouse brain via selective inhibition of its COX-2-mediated oxygenation.5, 8, 11, 14-eicosatetraynoic acid suppresses CCL2/MCP-1 expression in IFN-γ-stimulated astrocytes by increasing MAPK phosphatase-1 mRNA stability.Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.Update on the role of cannabinoid receptors after ischemic stroke.CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity.Pharmacological activation of CB2 receptors counteracts the deleterious effect of ethanol on cell proliferation in the main neurogenic zones of the adult rat brain.Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential.Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa.Cannabinoid ester constituents from high-potency Cannabis sativa.Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease.
P2860
Q21093231-F61AFFC9-16AC-4EEB-879C-60B4BD343141Q24646738-ABE60DCE-DA60-4997-AD0D-3100B07CD66FQ26746192-9FF78037-6284-4A8C-9F08-919C684C9AC3Q27014154-F9A9BA50-F5E4-4071-9FD2-88D48A18D2FFQ28241318-F9457CB8-9BB0-4B40-86B4-666522B12122Q28283718-2CADB89E-9734-4922-9306-99F5FD912FCDQ28537808-2274BEC4-E640-48A7-83EE-AA7FADC54327Q29042501-D337DFFA-4094-4622-947D-DD20AE410AAEQ30363270-C4E43FA7-ACEB-4948-BF9E-2655D560E986Q30417551-98DC2D30-82A2-497A-84FD-BF0A197CE3D0Q30470076-6459403C-9BF1-4DBF-B8FA-CEE90E78F0E7Q33664105-CD68249F-8DD8-4D64-9BD5-E59C513CEDE2Q33714587-B55B0A57-6199-4723-A5FD-35FD68495B2EQ33765040-6C955237-EAE1-4463-A5A6-85F2985ADE62Q33997873-23637CEC-DCAD-4E1B-BFAB-9C5767AFBC44Q34004234-5E7EDA54-2C8B-42A0-A852-BCBEDB06D2E9Q34098185-EABB9EFF-0B72-4570-B6C0-B0C5B47C3804Q34156640-AB6ED272-C05D-407D-B8CB-959A2B67DDCAQ34403197-18E846C9-EF1D-4376-A34F-62BD696F6F94Q34509920-2D92C34F-E160-436D-8948-91402D8B017EQ34591087-F4251998-2AA1-4CD4-8251-A689722D364FQ34679432-D1C62C01-F7BE-4798-8749-1CD170421030Q35016514-45187CF8-EB0F-4D6D-80E1-A89A45DD13F8Q35028750-DCAC6F75-5211-4154-99D1-695F27A28ACAQ35030056-1B7607BC-1CB9-4322-AC05-39EF2C60A287Q35103574-991F0FC6-5403-4745-9FAE-6553FB218976Q35184435-D702928E-EA56-4A83-9373-7D6BE04C5F9EQ35193282-7D405F8F-CAF2-4418-A4E1-7542CC60B65BQ35532072-19E78012-DDAE-4D50-952D-7705A7AF850FQ35574768-BDAE0F27-7FF9-4E88-B13D-4EEE488BA767Q35814389-A2B38FDF-B989-407A-BB28-335B24AD7922Q35842324-F50BBD30-502F-428F-B0DD-5FBED34E7F9AQ35863912-C9414981-59B6-48F9-A351-29146D09526DQ35915645-B5A7CFFC-005C-4582-8E2D-58D8F5DB7B72Q36071533-1BE2EC45-1E2A-4299-B4E5-D40811C1D520Q36103855-C21E6D42-D627-4DB8-A93D-28E82B8EDE06Q36408464-E7A8F5CB-94F3-4C8F-91F2-192DAD60F55CQ36936213-D8CD07D9-C954-44B5-A110-23CD13F0B1EAQ36942670-24A94F5B-2421-43D8-8F6F-AFC108919425Q37120339-527BC697-9A25-4730-85AB-38A0AC755037
P2860
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
@ast
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
@en
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
@nl
type
label
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
@ast
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
@en
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
@nl
prefLabel
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
@ast
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
@en
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
@nl
P2860
P921
P3181
P1476
The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration
@en
P2093
John C Ashton
P2860
P3181
P356
10.2174/157015907780866884
P407
P577
2007-01-01T00:00:00Z